<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02461004</url>
  </required_header>
  <id_info>
    <org_study_id>152BE15016</org_study_id>
    <nct_id>NCT02461004</nct_id>
  </id_info>
  <brief_title>CKD-391 Pharmacokinetic Study</brief_title>
  <official_title>Clinical Trial to Assess the Pharmacokinetic Characteristics and Safety/Tolerability of CKD-391 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, open-label, 2-way crossover study to compare the pharmacokinetics and safety
      CKD-391 to coadministration Atorvastatin and Ezetimibe in health volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the CKD-391 (Experimental product) to the dose Atorvastatin calcium and Ezetimibe
      combination in health male subjects is the purpose of this trial.

      Following are evaluated in this trial; Characteristics and safety/Tolerability Of CKD-391.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUClast</measure>
    <time_frame>up to 96 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>up to 96 hours post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>up to 96 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2</measure>
    <time_frame>up to 96 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf</measure>
    <time_frame>up to 96 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>up to 24days post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>TR group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CKD-391 and combination dose of Atrovastatin and Ezetimibe in order</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RT group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>combination dose of Atrovastatin and Ezetimibe and CKD-391 in order</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-391</intervention_name>
    <description>Investigational product is prescribed to all of radomized subjects for two times.</description>
    <arm_group_label>TR group</arm_group_label>
    <arm_group_label>RT group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atrovastatin and Ezetimibe combination therapy</intervention_name>
    <description>Investigational products are prescribed to all of radomized subjects for two times.</description>
    <arm_group_label>TR group</arm_group_label>
    <arm_group_label>RT group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Bwt &gt;=50kg, BMI 18~29

          -  signed the informed consent form prior to the study participation

        Exclusion Criteria:

          -  Clinically significant disease

          -  Subject has signs of symptoms of acute disease within 28 days of starting
             administration of investigational drug

          -  Clinically significant allergic disease

          -  Impossible to taking the institutional standard meal

          -  Previously donate whole blood within 60 days or component blood within 20 days

          -  Previously participated in other trial within 90 days

          -  Continued to be taking caffeine (caffeine &gt; 5 cup/day), drinking(alcohol &gt; 30 g/day)
             or cannot stop drinking or severe heavy smoker(cigarette &gt; 10 cigarettes per
             day)during clinical trials

          -  An impossible one who participates in clinical trial by investigator's decision
             including laboratory test result
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ji Young Park, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Korea University Anam Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2015</study_first_submitted>
  <study_first_submitted_qc>June 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2015</study_first_posted>
  <last_update_submitted>October 13, 2016</last_update_submitted>
  <last_update_submitted_qc>October 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dyslipidemia</keyword>
  <keyword>CKD-391</keyword>
  <keyword>Atorvastatin</keyword>
  <keyword>Ezetimibe</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

